Savara Inc. (SVRA) Stock

Savara Inc. (SVRA) is a Healthcare stock trading at $5.47 (as of 2026-06-18), with a market capitalization of $1.07B and a trailing P/E of -9.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis.

Valuation — source: SEC EDGAR (first-party)
Price$5.47
Market Cap$1.07B
P/E Ratio-9.3
EV / EBITDA-7.9
Price / Book-2483.97
DCF Value (model)$-8.39
DCF Upside vs Price-253.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$257000.00
Net Margin-19305.4%
Return on Equity30182.3%
Debt / Equity-70.09
Current Ratio13.47
Valuation vs Sector & Industry
Stock P/E-9.3
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-144.3%
vs Industry-153.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderNEA Management Company, LLC ($133.61M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMatthew Pauls
Employees59
CountryUS
IPO Date2017-04-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Schrödinger, Inc. (SDGR)
  • Palvella Therapeutics, Inc. (PVLA)
  • Septerna, Inc. (SEPN)
  • Omeros Corporation (OMER)
  • Amphastar Pharmaceuticals, Inc. (AMPH)
  • Phathom Pharmaceuticals, Inc. (PHAT)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Inhibrx Biosciences, Inc. (INBX)
SVRA earnings history · SVRA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.